More recently, soluble PDL1 serum concentration has been associated with a high metabolic tumor burden, suggesting that the levels of PDL1 may reflect the expansion of tumor volume and tumor lysis during ICI treatment [31]. This evidence concerns the gene CD274 and neoplasm.